<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31096306</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>11</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>06</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1098-9064</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>45</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Seminars in thrombosis and hemostasis</Title>
          <ISOAbbreviation>Semin Thromb Hemost</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Tissue Factor and Cancer: Regulation, Tumor Growth, and Metastasis.</ArticleTitle>
        <Pagination>
          <StartPage>385</StartPage>
          <EndPage>395</EndPage>
          <MedlinePgn>385-395</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0039-1687894</ELocationID>
        <Abstract>
          <AbstractText>There is a strong relationship between tissue factor (TF) and cancer. Many cancer cells express high levels of both full-length TF and alternatively spliced (as) TF. TF expression in cancer is associated with poor prognosis. In this review, the authors summarize the regulation of TF expression in cancer cells and the roles of TF and asTF in tumor growth and metastasis. A variety of different signaling pathways, transcription factors and micro ribonucleic acids regulate TF gene expression in cancer cells. The TF/factor VIIa complex enhances tumor growth by activating protease-activated receptor 2 signaling and by increasing the expression of angiogenic factors, such as vascular endothelial growth factor. AsTF increases tumor growth by enhancing integrin β1 signaling. TF and asTF also contribute to metastasis via multiple thrombin-dependent and independent mechanisms that include protecting tumor cells from natural killer cells. Finally, a novel anticancer therapy is using tumor TF as a target to deliver cytotoxic drugs to the tumor. TF may be useful in diagnosis, prognosis, and treatment of cancer.</AbstractText>
          <CopyrightInformation>Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hisada</LastName>
            <ForeName>Yohei</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Oncology, Department of Medicine, Thrombosis and Hemostasis Program, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mackman</LastName>
            <ForeName>Nigel</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Oncology, Department of Medicine, Thrombosis and Hemostasis Program, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA190717</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32 HL007149</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>05</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Semin Thromb Hemost</MedlineTA>
        <NlmUniqueID>0431155</NlmUniqueID>
        <ISSNLinking>0094-6176</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018796">Immunoconjugates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9035-58-9</RegistryNumber>
          <NameOfSubstance UI="D013925">Thromboplastin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018796" MajorTopicYN="N">Immunoconjugates</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013925" MajorTopicYN="N">Thromboplastin</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Nigel Mackman is a consultant for Seattle Genetics. Yohei Hisada has no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31096306</ArticleId>
        <ArticleId IdType="mid">NIHMS1030943</ArticleId>
        <ArticleId IdType="pmc">PMC6546519</ArticleId>
        <ArticleId IdType="doi">10.1055/s-0039-1687894</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Grover SP, Mackman N. Tissue Factor: An Essential Mediator of Hemostasis and Trigger of Thrombosis.
Arterioscler Thromb Vasc Biol
2018</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29437578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bogdanov VY, Balasubramanian V, Hathcock J, et al.
Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein.
Nat Med
2003;9(4):458–462</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12652293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Censarek P, Bobbe A, Grandoch M, Schror K, Weber AA. Alternatively spliced human tissue factor (asHTF) is not pro-coagulant.
Thromb Haemost
2007;97(1):11–14</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17200764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bogdanov VY, Versteeg HH. “Soluble Tissue Factor” in the 21st Century: Definitions, Biochemistry, and Pathophysiological Role in Thrombus Formation.
Semin Thromb Hemost
2015;41(7):700–707</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4827326</ArticleId>
            <ArticleId IdType="pubmed">26408917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis.
Am J Pathol
1989;134(5):1087–1097</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1879887</ArticleId>
            <ArticleId IdType="pubmed">2719077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients.
Blood
2013;122(11):1873–1880</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3772497</ArticleId>
            <ArticleId IdType="pubmed">23798713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nitori N, Ino Y, Nakanishi Y, et al.
Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma.
Clin Cancer Res
2005;11(7):2531–2539</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15814630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaido T, Oe H, Yoshikawa A, et al.
Tissue factor is a useful prognostic factor of recurrence in hepatocellular carcinoma in 5-year survivors.
Hepatogastroenterology
2005;52(65):1383–1387</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16201079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seto S, Onodera H, Kaido T, et al.
Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis.
Cancer
2000;88(2):295–301</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10640960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ueno T, Toi M, Koike M, Nakamura S, Tominaga T. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration.
Br J Cancer
2000;83(2):164–170</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2363475</ArticleId>
            <ArticleId IdType="pubmed">10901365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akashi T, Furuya Y, Ohta S, Fuse H. Tissue factor expression and prognosis in patients with metastatic prostate cancer.
Urology
2003;62(6):1078–1082</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14665359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patry G, Hovington H, Larue H, et al.
Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer.
Int J Cancer
2008;122(7):1592–1597</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18058798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamashita H, Kitayama J, Ishikawa M, Nagawa H. Tissue factor expression is a clinical indicator of lymphatic metastasis and poor prognosis in gastric cancer with intestinal phenotype.
J Surg Oncol
2007;95(4):324–331</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17066404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L, Luo G, Tan Y, et al.
Immunolocalisation of tissue factor in esophageal cancer is correlated with intratumoral angiogenesis and prognosis of the patient.
Acta Histochem
2010;112(3):233–239</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19428056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poon RT, Lau CP, Ho JW, et al.
Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma.
Clin Cancer Res
2003;9(14):5339–5345</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14614019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zelaya H, Rothmeier AS, Ruf W. Tissue factor at the crossroad of coagulation and cell signaling.
J Thromb Haemost
2018;16(10):1941–1952</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30030891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Belting M, Ahamed J, Ruf W. Signaling of the tissue factor coagulation pathway in angiogenesis and cancer.
Arterioscler Thromb Vasc Biol
2005;25(8):1545–1550</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15905465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sever R, Brugge JS. Signal transduction in cancer.
Cold Spring Harb Perspect Med
2015;5(4)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4382731</ArticleId>
            <ArticleId IdType="pubmed">25833940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rak J, Mitsuhashi Y, Bayko L, et al.
Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis.
Cancer Res
1995;55(20):4575–4580</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7553632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rak J, Mitsuhashi Y, Sheehan C, et al.
Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts.
Cancer Res
2000;60(2):490–498</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10667605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rong Y, Post DE, Pieper RO, et al.
PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma.
Cancer Res
2005;65(4):1406–1413</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15735028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Provencal M, Labbe D, Veitch R, et al.
c-Met activation in medulloblastoma induces tissue factor expression and activity: effects on cell migration.
Carcinogenesis
2009;30(7):1089–1096</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19359592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rong Y, Belozerov VE, Tucker-Burden C, et al.
Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.
Cancer Res
2009;69(6):2540–2549</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2759716</ArticleId>
            <ArticleId IdType="pubmed">19276385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Unruh D, Schwarze SR, Khoury L, et al.
Mutant IDH1 and thrombosis in gliomas.
Acta Neuropathol
2016;132(6):917–930</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5640980</ArticleId>
            <ArticleId IdType="pubmed">27664011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D’Asti E, Huang A, Kool M, et al.
Tissue Factor Regulation by miR-520g in Primitive Neuronal Brain Tumor Cells: A Possible Link between Oncomirs and the Vascular Tumor Microenvironment.
Am J Pathol
2016;186(2):446–459</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5808154</ArticleId>
            <ArticleId IdType="pubmed">26687818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou JN, Ljungdahl S, Shoshan MC, Swedenborg J, Linder S. Activation of tissue-factor gene expression in breast carcinoma cells by stimulation of the RAF-ERK signaling pathway.
Mol Carcinog
1998;21(4):234–243</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9585253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu JL, Xing R, Milsom C, Rak J. Modulation of the oncogene-dependent tissue factor expression by kinase suppressor of ras 1.
Thromb Res
2010;126(1):e6–10</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20553947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun L, Liu Y, Lin S, et al.
Early growth response gene-1 and hypoxia-inducible factor-1alpha affect tumor metastasis via regulation of tissue factor.
Acta Oncol
2013;52(4):842–851</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23409769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bourcy M, Suarez-Carmona M, Lambert J, et al.
Tissue Factor Induced by Epithelial-Mesenchymal Transition Triggers a Procoagulant State That Drives Metastasis of Circulating Tumor Cells.
Cancer Res
2016;76(14):4270–4282</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27221703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X, Yu H, Lou JR, et al.
MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells.
J Biol Chem
2011;286(2):1429–1435</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3020751</ArticleId>
            <ArticleId IdType="pubmed">21059650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teruel R, Perez-Sanchez C, Corral J, et al.
Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome.
J Thromb Haemost
2011;9(10):1985–1992</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21794077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu JL, May L, Lhotak V, et al.
Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis.
Blood
2005;105(4):1734–1741</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15494427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rao B, Gao Y, Huang J, et al.
Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis.
Int J Colorectal Dis
2011;26(5):593–601</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21404058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu G, Li H, Wang X, et al.
MicroRNA-19a targets tissue factor to inhibit colon cancer cells migration and invasion.
Mol Cell Biochem
2013;380(1–2):239–247</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23666757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewis CS, Elnakat Thomas H, Orr-Asman M, et al.
mTOR kinase inhibition reduces tissue factor expression and growth of pancreatic neuroendocrine tumors.
J Thromb Haemost
2018</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6345540</ArticleId>
            <ArticleId IdType="pubmed">30472780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Milsom CC, Yu JL, Mackman N, et al.
Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis.
Cancer Res
2008;68(24):10068–10076</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2834285</ArticleId>
            <ArticleId IdType="pubmed">19074872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kato S, Pinto M, Carvajal A, et al.
Tissue factor is regulated by epidermal growth factor in normal and malignant human endometrial epithelial cells.
Thromb Haemost
2005;94(2):444–453</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16113838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Regina S, Rollin J, Blechet C, et al.
Tissue factor expression in non-small cell lung cancer: relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation.
J Thorac Oncol
2008;3(7):689–697</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18594312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jolly MK, Ware KE, Gilja S, Somarelli JA, Levine H. EMT and MET: necessary or permissive for metastasis?
Mol Oncol
2017;11(7):755–769</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5496498</ArticleId>
            <ArticleId IdType="pubmed">28548345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garnier D, Magnus N, Lee TH, et al.
Cancer cells induced to express mesenchymal phenotype release exosome-like extracellular vesicles carrying tissue factor.
J Biol Chem
2012;287(52):43565–43572</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3527943</ArticleId>
            <ArticleId IdType="pubmed">23118232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dang L, White DW, Gross S, et al.
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Nature
2009;462(7274):739–744</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2818760</ArticleId>
            <ArticleId IdType="pubmed">19935646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turcan S, Rohle D, Goenka A, et al.
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
Nature
2012;483(7390):479–483</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3351699</ArticleId>
            <ArticleId IdType="pubmed">22343889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chuang TD, Luo X, Panda H, Chegini N. miR-93/106b and their host gene, MCM7, are differentially expressed in leiomyomas and functionally target F3 and IL-8.
Mol Endocrinol
2012;26(6):1028–1042</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3355544</ArticleId>
            <ArticleId IdType="pubmed">22556343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D’Asti E, Anderson GM, Rak J. Inhibition of tissue factor signaling in breast tumour xenografts induces widespread changes in the microRNA expression profile.
Biochem Biophys Res Commun
2017;494(3–4):700–705</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29111325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magnus N, Gerges N, Jabado N, Rak J. Coagulation-related gene expression profile in glioblastoma is defined by molecular disease subtype.
J Thromb Haemost
2013;11(6):1197–1200</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23582031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tawil N, Chennakrishnaiah S, Bassawon R, et al.
Single cell coagulomes as constituents of the oncogene-driven coagulant phenotype in brain tumours.
Thromb Res
2018;164
Suppl 1:S136–S142</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29703472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magnus N, Garnier D, Meehan B, et al.
Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations.
Proc Natl Acad Sci U S A
2014;111(9):3544–3549</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3948265</ArticleId>
            <ArticleId IdType="pubmed">24520174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hisada Y, Mackman N. Mouse models of cancer-associated thrombosis.
Thromb Res
2018;164
Suppl 1:S48–S53</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5942599</ArticleId>
            <ArticleId IdType="pubmed">29306575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McEachron T, Mackman N. Tumors, ticks and tissue factor.
J Thromb Haemost
2009;7(11):1852–1854</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2834282</ArticleId>
            <ArticleId IdType="pubmed">19694942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang JG, Geddings JE, Aleman MM, et al.
Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer.
Blood
2012;119(23):5543–5552</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3369688</ArticleId>
            <ArticleId IdType="pubmed">22547577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geddings JE, Hisada Y, Boulaftali Y, et al.
Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice.
J Thromb Haemost
2016;14(1):153–166</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4715578</ArticleId>
            <ArticleId IdType="pubmed">26516108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loukopoulos P, Kanetaka K, Takamura M, et al.
Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity.
Pancreas
2004;29(3):193–203</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15367885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeRose YS, Wang G, Lin YC, et al.
Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes.
Nat Med
2011;17(11):1514–1520</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3553601</ArticleId>
            <ArticleId IdType="pubmed">22019887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao X, Liu Z, Yu L, et al.
Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma.
Neuro Oncol
2012;14(5):574–583</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3337308</ArticleId>
            <ArticleId IdType="pubmed">22459127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McEvoy J, Ulyanov A, Brennan R, et al.
Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma.
PLoS One
2012;7(8):e42739.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3423419</ArticleId>
            <ArticleId IdType="pubmed">22916154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruf W
Tissue factor and cancer.
Thromb Res
2012;130
Suppl 1:S84–87</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3882024</ArticleId>
            <ArticleId IdType="pubmed">23026674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Deng Y, Luther T, et al.
Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice.
J Clin Invest
1994;94(3):1320–1327</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC295218</ArticleId>
            <ArticleId IdType="pubmed">7521887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kakkar AK, Chinswangwatanakul V, Lemoine NR, Tebbutt S, Williamson RC. Role of tissue factor expression on tumour cell invasion and growth of experimental pancreatic adenocarcinoma.
Br J Surg
1999;86(7):890–894</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10417560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koizume S, Jin MS, Miyagi E, et al.
Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII.
Cancer Res
2006;66(19):9453–9460</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17018600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hembrough TA, Swartz GM, Papathanassiu A, et al.
Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism.
Cancer Res
2003;63(11):2997–3000</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12782609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao J, Aguilar G, Palencia S, Newton E, Abo A. rNAPc2 inhibits colorectal cancer in mice through tissue factor.
Clin Cancer Res
2009;15(1):208–216</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19118048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Versteeg HH, Schaffner F, Kerver M, et al.
Inhibition of tissue factor signaling suppresses tumor growth.
Blood
2008;111(1):190–199</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2200804</ArticleId>
            <ArticleId IdType="pubmed">17901245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palumbo JS, Talmage KE, Massari JV, et al.
Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms.
Blood
2007;110(1):133–141</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1896107</ArticleId>
            <ArticleId IdType="pubmed">17371949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hjortoe GM, Petersen LC, Albrektsen T, et al.
Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration.
Blood
2004;103(8):3029–3037</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2837482</ArticleId>
            <ArticleId IdType="pubmed">15070680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Versteeg HH, Schaffner F, Kerver M, et al.
Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice.
Cancer Res
2008;68(17):7219–7227</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2596617</ArticleId>
            <ArticleId IdType="pubmed">18757438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schaffner F, Versteeg HH, Schillert A, et al.
Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development.
Blood
2010;116(26):6106–6113</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3031395</ArticleId>
            <ArticleId IdType="pubmed">20861457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ryden L, Grabau D, Schaffner F, et al.
Evidence for tissue factor phosphorylation and its correlation with protease-activated receptor expression and the prognosis of primary breast cancer.
Int J Cancer
2010;126(10):2330–2340</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2847028</ArticleId>
            <ArticleId IdType="pubmed">19795460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rothmeier AS, Liu E, Chakrabarty S, et al.
Identification of the integrin-binding site on coagulation factor VIIa required for proangiogenic PAR2 signaling.
Blood
2018;131(6):674–685</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5805488</ArticleId>
            <ArticleId IdType="pubmed">29246902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu J, May L, Milsom C, et al.
Contribution of host-derived tissue factor to tumor neovascularization.
Arterioscler Thromb Vasc Biol
2008;28(11):1975–1981</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2848475</ArticleId>
            <ArticleId IdType="pubmed">18772494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Darmoul D, Gratio V, Devaud H, Lehy T, Laburthe M. Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells.
Am J Pathol
2003;162(5):1503–1513</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1851194</ArticleId>
            <ArticleId IdType="pubmed">12707033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keshava S, Sahoo S, Tucker TA, et al.
Endothelial cell protein C receptor opposes mesothelioma growth driven by tissue factor.
Cancer Res
2013;73(13):3963–3973</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3702650</ArticleId>
            <ArticleId IdType="pubmed">23539451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tekin C, Shi K, Daalhuisen JB, et al.
PAR1 signaling on tumor cells limits tumor growth by maintaining a mesenchymal phenotype in pancreatic cancer.
Oncotarget
2018;9(62):32010–32023</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6112838</ArticleId>
            <ArticleId IdType="pubmed">30174793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Queiroz KC, Shi K, Duitman J, et al.
Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance.
Int J Cancer
2014;135(10):2294–2304</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24436106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adams GN, Sharma BK, Rosenfeldt L, et al.
Protease-activated receptor-1 impedes prostate and intestinal tumor progression in mice.
J Thromb Haemost
2018</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6214773</ArticleId>
            <ArticleId IdType="pubmed">30152921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hobbs JE, Zakarija A, Cundiff DL, et al.
Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model.
Thromb Res
2007;120
Suppl 2:S13–21</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18023707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kocaturk B, Van den Berg YW, Tieken C, et al.
Alternatively spliced tissue factor promotes breast cancer growth in a beta1 integrin-dependent manner.
Proc Natl Acad Sci U S A
2013;110(28):11517–11522</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3710867</ArticleId>
            <ArticleId IdType="pubmed">23801760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kocaturk B, Tieken C, Vreeken D, et al.
Alternatively spliced tissue factor synergizes with the estrogen receptor pathway in promoting breast cancer progression.
J Thromb Haemost
2015;13(9):1683–1693</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4560996</ArticleId>
            <ArticleId IdType="pubmed">26179105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Unruh D, Unlu B, Lewis CS, et al.
Antibody-based targeting of alternatively spliced tissue factor: a new approach to impede the primary growth and spread of pancreatic ductal adenocarcinoma.
Oncotarget
2016;7(18):25264–25275</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5041902</ArticleId>
            <ArticleId IdType="pubmed">26967388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Unruh D, Turner K, Srinivasan R, et al.
Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma.
Int J Cancer
2014;134(1):9–20</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4122306</ArticleId>
            <ArticleId IdType="pubmed">23754313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis.
Crit Rev Oncog
2013;18(1–2):43–73</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3597235</ArticleId>
            <ArticleId IdType="pubmed">23237552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites.
Nat Rev Cancer
2002;2(8):563–572</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12154349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shigemori C, Wada H, Matsumoto K, et al.
Tissue factor expression and metastatic potential of colorectal cancer.
Thromb Haemost
1998;80(6):894–898</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9869156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis.
Proc Natl Acad Sci U S A
1992;89(24):11832–11836</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC50651</ArticleId>
            <ArticleId IdType="pubmed">1465406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gil-Bernabe AM, Ferjancic S, Tlalka M, et al.
Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice.
Blood
2012;119(13):3164–3175</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22327225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amirkhosravi A, Meyer T, Chang JY, et al.
Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma.
Thromb Haemost
2002;87(6):930–936</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12083498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation.
Proc Natl Acad Sci U S A
1995;92(18):8205–8209</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC41125</ArticleId>
            <ArticleId IdType="pubmed">7667269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mueller BM, Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis.
J Clin Invest
1998;101(7):1372–1378</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC508714</ArticleId>
            <ArticleId IdType="pubmed">9525979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yokota N, Zarpellon A, Chakrabarty S, et al.
Contributions of thrombin targets to tissue factor-dependent metastasis in hyperthrombotic mice.
J Thromb Haemost
2014;12(1):71–81</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3947224</ArticleId>
            <ArticleId IdType="pubmed">24175924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palumbo JS, Kombrinck KW, Drew AF, et al.
Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells.
Blood
2000;96(10):3302–3309</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11071621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palumbo JS, Potter JM, Kaplan LS, et al.
Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice.
Cancer Res
2002;62(23):6966–6972</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12460914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Camerer E, Qazi AA, Duong DN, et al.
Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis.
Blood
2004;104(2):397–401</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15031212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palumbo JS, Talmage KE, Massari JV, et al.
Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells.
Blood
2005;105(1):178–185</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15367435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi X, Gangadharan B, Brass LF, Ruf W, Mueller BM. Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis.
Mol Cancer Res
2004;2(7):395–402</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15280447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Villares GJ, Zigler M, Dobroff AS, et al.
Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype.
Proc Natl Acad Sci U S A
2011;108(2):626–631</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3021062</ArticleId>
            <ArticleId IdType="pubmed">21187389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang X, Molema G, King S, et al.
Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature.
Science
1997;275(5299):547–550</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8999802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ran S, Gao B, Duffy S, et al.
Infarction of solid Hodgkin’s tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature.
Cancer Res
1998;58(20):4646–4653</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9788617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu C, Huang H, Donate F, et al.
Prostate-specific membrane antigen directed selective thrombotic infarction of tumors.
Cancer Res
2002;62(19):5470–5475</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12359755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Sheikh A, Borgstrom P, Bhattacharjee G, Belting M, Edgington TS. A selective tumor microvasculature thrombogen that targets a novel receptor complex in the tumor angiogenic microenvironment.
Cancer Res
2005;65(23):11109–11117</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16322261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Z, Sun Y, Garen A. Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model.
Proc Natl Acad Sci U S A
1999;96(14):8161–8166</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC22205</ArticleId>
            <ArticleId IdType="pubmed">10393965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Z, Garen A. Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy.
Proc Natl Acad Sci U S A
2000;97(16):9221–9225</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC16849</ArticleId>
            <ArticleId IdType="pubmed">10922073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Z, Garen A. Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer.
Proc Natl Acad Sci U S A
2001;98(21):12180–12185</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC59788</ArticleId>
            <ArticleId IdType="pubmed">11593034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto Y, Hyodo I, Koga Y, et al.
Enhanced antitumor effect of anti-tissue factor antibody-conjugated epirubicin-incorporating micelles in xenograft models.
Cancer Sci
2015;106(5):627–634</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4452165</ArticleId>
            <ArticleId IdType="pubmed">25711681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sugaya A, Hyodo I, Koga Y, et al.
Utility of epirubicin-incorporating micelles tagged with anti-tissue factor antibody clone with no anticoagulant effect.
Cancer Sci
2016;107(3):335–340</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4814265</ArticleId>
            <ArticleId IdType="pubmed">26676840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Breij EC, de Goeij BE, Verploegen S, et al.
An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.
Cancer Res
2014;74(4):1214–1226</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24371232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koga Y, Manabe S, Aihara Y, et al.
Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts.
Int J Cancer
2015;137(6):1457–1466</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5024081</ArticleId>
            <ArticleId IdType="pubmed">25704403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X, Li Q, Zhao H, et al.
Pathological expression of tissue factor confers promising antitumor response to a novel therapeutic antibody SC1 in triple negative breast cancer and pancreatic adenocarcinoma.
Oncotarget
2017;8(35):59086–59102</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5601716</ArticleId>
            <ArticleId IdType="pubmed">28938620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Francisco JA, Cerveny CG, Meyer DL, et al.
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.
Blood
2003;102(4):1458–1465</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12714494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsumura R, Manabe S, Takashima H, et al.
Influence of the dissociation rate constant on the intra-tumor distribution of antibody-drug conjugate against tissue factor.
J Control Release
2018;284:49–56</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29906553</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
